Phase 1 Trial of GCAR1 CAR-T Therapy for GPNMB-Expressing Tumors Initiated in Canada
A Phase 1 trial is underway to evaluate the safety and tolerability of GCAR1 CAR-T therapy in patients with relapsed/refractory GPNMB-expressing solid tumors.
Asset / Drug
Drug and asset intelligence for GCAR1 with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No catalysts indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.